4 completed, 3 active not recruiting, 1 not yet recruiting, 1 recruiting. 10 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 4, Active not recruiting 3, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
Follow Plexiform Neurofibroma: new trials by email Literature Review of Plexiform Neurofibroma trials Research Report on Plexiform Neurofibroma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 Selumetinib - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 2 | Recruiting | University of Alabama at Birmingham | 200 | 2025-08-27 | 2026-05-29 |
| Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 Luvometinib Tablets - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 65 | 2025-06-12 | 2025-06-17 |
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 FCN-159 - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 160 | 2021-03-26 | 2024-11-12 |
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Mirdametinib (PD-0325901) oral capsule or dispersible tablet - Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1) | Phase 2 | Active not recruiting | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 114 | 2019-09-29 | 2026-10-06 |
| Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Selumetinib - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Completed | Great Ormond Street Hospital for Children NHS Foundation Trust | 14 | 2019-09-26 | 2024-04-04 |
| Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. Trametinib - Low-grade Glioma, Plexiform Neurofibroma | Phase 2 | Active not recruiting | St. Justine's Hospital | 114 | 2018-08-16 | 2026-04-24 |
| Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Binimetinib - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 2 | Completed | University of Alabama at Birmingham | 45 | 2017-11-28 | 2025-05-02 |
| Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas RAD001: Everolimus - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 30 | 2011-04-01 | 2014-11-14 |
| Study of PEG-Intron for Plexiform Neurofibromas PEG-Intron - Plexiform Neurofibroma | Phase 2 | Completed | University of Pittsburgh | 86 | 2006-12-01 | 2017-11-06 |
| AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine Cediranib Maleate - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 2 | Terminated | National Cancer Institute (NCI) | 26 | 2006-05-01 | 2017-08-18 |
Neurofibroma, Plexiform (10) · Neurofibromatosis 1 (9) · Neurofibromatoses (3) · Neurofibroma (2) · Brain Neoplasms (1) · Glioma (1) · Optic Nerve Glioma (1) · Peripheral Nervous System Neoplasms (1)
Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms, Nerve Tissue (10) · Nerve Sheath Neoplasms (10) · Nervous System Diseases (10) · Nervous System Neoplasms (10) · Neuromuscular Diseases (10) · Peripheral Nervous System Diseases (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Genetic Diseases, Inborn (9) · Heredodegenerative Disorders, Nervous System (9) · Neoplastic Syndromes, Hereditary (9) · Neurocutaneous Syndromes (9) · Neurodegenerative Diseases (9) · Peripheral Nervous System Neoplasms (9)
AZD 6244 (2) · binimetinib (1) · cediranib (1) · mirdametinib (1) · peginterferon alfa-2b (1) · trametinib (1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (2) · University of Alabama at Birmingham (2) · Assistance Publique - Hôpitaux de Paris (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · National Cancer Institute (NCI) (1) · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (1) · St. Justine's Hospital (1) · University of Pittsburgh (1)
United States (6) · China (2) · Canada (1) · France (1) · Spain (1) · United Kingdom (1)
Bruce Korf, MD, PhD (1) · Darren Hargrave, MB Bch (1) · Dusica Babovic-Vuksanovic (1) · Jean Tersak, M.D. (1) · Pierre Wolkenstein, MD, PhD (1)
PMID 27510726, PMID 30339775, PMID 31881853, PMID 37400844, PMID 39514826, PMID 41139346
N01CM17104 (1), N01CM62205 (1), P30CA015083 (1)